Clinical Trials Sponsored by Ipsen

Total 404 results

Ipsen

Recruiting

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

Melanoma | Colorectal Cancer | Solid Tumor | Head and Neck Squamous Cell Carcinoma | Pancreatic Ductal Adenocarcinoma

United States
Ipsen

Recruiting

CARegiver BURden, Effectiveness and Other Health Care Measures on Functional Disability, in Patients Treated With Abobotulinumtoxin A for Upper Limb Spasticity (CARBUR)

Upper Limb Injury

France
Ipsen

Recruiting

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults (E-BEOND)

Episodic Migraine

United States, Canada, Czechia, Georgia, Germany, Poland, Spain, France
Ipsen

Recruiting

A Study to Observe Demography and the Outcome of Prostate Cancer Patients Treated With 6-month Triptorelin Formulation in Italy (REAL6T)

Prostate Cancer

Italy
Ipsen

Recruiting

A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas (SIRACUSA)

Metastatic Pancreatic Adenocarcinoma

Spain, France, Italy, Hungary, Australia, Germany, Portugal
Ipsen

Recruiting

A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults (CaboCombo)

Advanced Renal Cell Carcinoma

France, Korea, Republic of, Italy, Norway, United Kingdom, Greece, Saudi Arabia, Belgium
Ipsen

Recruiting

Effectiveness and Safety of SMART [Spastic Muscle Palpation by Anatomic Landscape for BoNT-A (Botulinumtoxin-A) Injection to Reduce Muscle Tone] BoNT-A Therapy With Dysport® in Patients With Post-stroke Chronic Upper Limb Spasticity (ULS) in Real-life Setting.

Post-Stroke Chronic Upper Limb Spasticity

Germany
Ipsen

Recruiting

A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity. (DIRECTION)

Upper Limb Spasticity

United States, France, Canada, Puerto Rico
Ipsen

Recruiting

Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

IGF1 Deficiency

Spain, United States, Italy, France, United Kingdom, Germany, Austria, French Guiana, Poland, Sweden, Martinique
Ipsen

Active, not recruiting

A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072

Neuroendocrine Tumors

Austria, Denmark, Switzerland, Australia, United Kingdom, France
Ipsen

Active, not recruiting

Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors (CaboPoint)

Locally Advanced or Metastatic Renal Cell Carcinoma

Spain, France, United Kingdom, Switzerland, Germany, Netherlands, Austria
Ipsen

Active, not recruiting

Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate

Metastatic Prostate Cancer | Advanced Prostate Cancer | Locally Advanced Prostate Cancer

China
Ipsen

Active, not recruiting

Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) (ELATIVE)

Primary Biliary Cirrhosis

United States, France, Spain, Belgium, Germany, Switzerland, Brazil, United Kingdom, Argentina, Canada, Chile, Italy, South Africa, Turkey
Ipsen

Completed

Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer (RESILIENT)

Small Cell Lung Cancer

Spain, United States, France, Taiwan, Korea, Republic of, Germany, China, Belgium, Italy, Brazil, Ukraine, Australia, Russian Federation, Serbia, Poland, Hungary, Turkey, Romania
Ipsen

Terminated

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

Neuroendocrine Tumors

United States, Australia, Austria, Canada, Denmark, France, Switzerland, United Kingdom
Ipsen

Completed

Study to Compare the Level of Elafibranor in Blood After Repeat Administration in Japanese and Non-Asian Healthy Participants

Healthy Volunteers

United States
Ipsen

Terminated

Study to Evaluate the Safety and Efficacy of IPN59011 in Improving the Appearance of Moderate to Severe Upper Facial Lines. (LONG-SET)

Moderate Upper Facial Lines | Severe Upper Facial Lines

Germany
Ipsen

Completed

Treatment of Aggressive Prostate Cancer in Real Life: Initiation, Schedule and Management of Triptorelin Treatment. (TALISMAN)

Prostate Cancer

France
Ipsen

Completed

An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome (ELECT)

Carcinoid Syndrome

United States, Turkey, Brazil, India, Ukraine, South Africa, Czechia, Latvia, Poland, Russian Federation, Serbia
Ipsen

Completed

Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour (NET729)

Non Functioning Entero-pancreatic Endocrine Tumour

United Kingdom, France, Spain, United States, Belgium, Czechia, Italy, Slovakia, Poland
Ipsen

Completed

Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

Pancreatic Cancer

United States, Spain, Australia
Ipsen

Completed

Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia

Cervical Dystonia

United States, Russian Federation
Ipsen

Completed

Dysport® Pediatric Lower Limb Spasticity Follow-on Study

Cerebral Palsy | Children | Muscle Spasticity

United States, France, Turkey, Chile, Mexico, Poland
Ipsen

Completed

Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines (BTX-A-HAC NG)

Moderate to Severe Glabellar Lines

France, Germany
Ipsen

Completed

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis

Detrusor Muscle Hyperactivity

France, Italy, Czechia, Germany, Poland
Ipsen

Terminated

Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours

Solid Tumor

United States
Ipsen

Completed

A Comparative Study to Evaluate the Effects and Mechanism of Action of Dysport®, Botox® and Xeomin® in the Extensor Digitorum Brevis Model in Healthy Adult Male Participants

Healthy Participants

United Kingdom
Ipsen

Terminated

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours (SPINET)

Neuroendocrine Tumors in Lung

Canada, United States, Germany, France, United Kingdom, Netherlands, Spain, Denmark, Italy, Austria, Poland
Ipsen

Completed

Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors (US NIS Cabo)

Locally Advanced or Metastatic Renal Cell Carcinoma

United States
Ipsen

Completed

Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis

Endometriosis

China
Ipsen

Completed

To Evaluate the Criteria for Renewal of Luteinizing Hormone-Releasing Hormone (LHRH) Analogue Treatment in Prostate Cancer Patients (ANAREN)

Prostate Cancer

Spain
Ipsen

Completed

A Study to Review Treatment Outcomes From Treatment With Dysport® Injections in Adults for Upper and/or Lower Limb Focal Spasticity (DYSCOVER)

Upper and/or Lower Limb Focal Spasticity

United Kingdom
Ipsen

Completed

An International Cross-sectional Survey to Evaluate the Burden of Fibrodysplasia Ossificans Progressiva (FOP) on Patients and Their Families.

Fibrodysplasia Ossificans Progressiva

United States
Ipsen

Completed

A Study to Assess Treatment Outcomes of abobotulinumtoxinA and onabotulinumtoxinA Treatments in Real Life Practice in Toxin-naïve Adult Patients With Limb Spasticity.

Spasticity Related to Any Cause Except Cerebral Palsy

United Kingdom
Ipsen

Completed

Study of the Effectiveness of ETIASA® (Sustained Release 5-Aminosalicylate) in Maintenance Treatment of Ulcerative Colitis (UC)

Ulcerative Colitis

China
Ipsen

Completed

To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

Gastro-Enteropancreatic Neuroendocrine Tumor

United States, Austria, Denmark
Ipsen

Withdrawn

Study on the Utilization of Cabozantinib in Adult Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) in 2nd Line Treatment Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy Under Real-real Life Clinical Setting in France. (CAROLINE)

Renal Cell Carcinoma
Ipsen

Completed

Relation Between Dose and Time to Reinjection of Botulinum Toxin-A in Patient With Poststroke Spasticity From a Real-world Healthcare Insurance Database. (Relax)

Post Stroke Spasticity

Netherlands
Ipsen

Completed

Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel (SALSA)

Acromegaly

United States
Ipsen

Completed

Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis

Carcinoma | Peritoneal Neoplasms | Intestinal Obstruction

France, Netherlands, Belgium
Ipsen

Completed

Adult Subjects Suffering From Lower Limb Spasticity Following Stroke (VALGAS)

Spasticity

Spain
Ipsen

Terminated

GP Extended Action Triptorelin (GREAT)

Prostate Cancer

United Kingdom
Ipsen

Completed

Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours

Neuroendocrine Tumours

Spain
Ipsen

Completed

DYSPORT™ Clinical & Health Economics Outcomes Registry in Cervical Dystonia (ANCHOR-CD)

Cervical Dystonia

United States
Ipsen

Completed

Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors. (ATLANT)

Neuroendocrine Tumours

Italy
Ipsen

Completed

Perception of Information and Quality of Life in Neuroendocrine Tumour on Lanreotide Autogel (OPERA)

Neuroendocrine Tumors

France
Ipsen

Terminated

Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency

Growth Disorders

France
Ipsen

Completed

Community-based Neuroendocrine Tumor (NET) Research Study

Gastroenteropancreatic Neuroendocrine Tumors

United States
Ipsen

Completed

Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors

Neuroendocrine Tumors

United States
Ipsen

Completed

Spasticity and Treatment Satisfaction Among Stroke Survivors (REBOT)

Spasticity as Sequela of Stroke

France

3

Subscribe